Abstract
The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Volume: 11 Issue: 3
Author(s): Sarmad Said and German T. Hernandez
Affiliation:
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Export Options
About this article
Cite this article as:
Said Sarmad and Hernandez T. German, Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/187152571103140120103032
DOI https://dx.doi.org/10.2174/187152571103140120103032 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Medical Complications of Binge Eating Disorder
Current Women`s Health Reviews Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design Prostate Cancer Horizons in the Development of Novel Anti-Cancer Strategies
Current Medicinal Chemistry - Anti-Cancer Agents Progresses in Nanopores Fabrications and Nanopore Sequencing
Nanoscience & Nanotechnology-Asia The Predictive Value of Vessel-Based Calcium Score in the Detection of Coronary Stenosis
Current Medical Imaging Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Polyoxometalates in Biomedicine: Update and Overview
Current Medicinal Chemistry Hip but Not Thigh Intramuscular Adipose Tissue is Associated with Poor Balance and Increased Temporal Gait Variability in Older Adults
Current Aging Science Continuous Glucose Monitoring: Physiological and Technological Challenges
Current Diabetes Reviews Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Antifungal Activity of Condensed Tannins from Stryphnodendron adstringens: Effect on Candida tropicalis Growth and Adhesion Properties
Current Pharmaceutical Biotechnology Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Genetic Polymorphism of LDLR (rs688) is Associated with Primary Intracerebral Hemorrhage
Current Neurovascular Research Refining Genetic Approaches for Identifying Behavioral Loci
Current Genomics Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Evaluation of Thiol/Disulfide Homeostasis in Pediatric Patients with Diabetic Ketoacidosis
Combinatorial Chemistry & High Throughput Screening